Cancer screening startup Ezra of New York City has secured $4 million in funding, which it plans to use to launch a prostate cancer screening program.
The funding round, led by venture capital firm Accomplice, is also supported by investors Credo Ventures, Esther Dyson, Founders Future, and Seedcamp, the company said.
The program will offer men the opportunity to get prostate MRI scans and have them analyzed by radiologists from imaging services provider RadNet's Lenox Hill Radiology facility in Manhattan. It is currently an invite-only program that costs participants $999 per year.
Ezra is also developing Ezra AI, an artificial intelligence (AI) technology designed to help radiologists analyze images. The company plans to seek U.S. Food and Drug Administration (FDA) clearance for the technology in 2019.
